Erratum: Signatures of mutational processes in human cancer (Nature (2013) 500 (415-421) DOI:10.1038/nature12477);Signatures of mutational processes in human cancer

Nature

Volumn 500, Issue 7463, 2013, Pages 415-421

  Alexandrov, Ludmil B ^a   Nik Zainal, Serena ^a,b   Wedge, David C ^a   Aparicio, Samuel A J R ^c,d   Behjati, Sam ^a,e   Biankin, Andrew V ^f,g,h,i,j   Bignell, Graham R ^a   Bolli, Niccolò ^a,k,l   Borg, Ake ^b   Børresen Dale, Anne Lise ^e,m   Boyault, Sandrine ⁿ   Burkhardt, Birgit ^o,p   Butler, Adam P ^a   Caldas, Carlos ^q   Davies, Helen R ^a   Desmedt, Christine ^r   Eils, Roland ^e   Eyfjörd, Jórunn Erla ^s   Foekens, John A ^t   Greaves, Mel ^u   Hosoda, Fumie ^v   Hutter, Barbara ^e   Ilicic, Tomislav ^a   Imbeaud, Sandrine ^w,x   Imielinsk, Marcin ^y   Jäger, Natalie ^e   Jones, David T W ^z   Jonas, David ^a   Knappskog, Stian ^t,aa   Koo, Marcel ^z   Lakhani, Sunil R ^ab   López Otín, Carlos ^ac   Martin, Sancha ^a   Munshi, Nikhil C ^ad,ae   Nakamura, Hiromi ^v   Northcott, Paul A ^z   Pajic, Marina ^f   Papaemmanuil, Elli ^a   Paradiso, Angelo ^af   Pearson, John V ^ag   Puente, Xose S ^ac   Raine, Keiran ^a   Ramakrishna, Manasa ^a   Richardson, Andrea L ^ah,ai,aj   Richter, Julia ^af   Rosenstiel, Philip ^ak   Schlesner, Matthias ^e   Schumacher, Ton N ^al   Span, Paul N ^al   Teague, Jon W ^a   Totoki, Yasushi ^v   Tutt, Andrew N J ^am   Valdés Mas, Rafael ^ac   Van Buuren, Marit M ^al   Van 'T Veer, Laura ^an   Vincent Salomon, Anne ^ao   Waddell, Nicola ^ag   Yates, Lucy R ^a   Zucman Rossi, Jessica ^w,x   Andrew Futreal, P ^a   McDermott, Ultan ^a   Lichter, Peter ^am   Meyerson, Matthew ^y,ah,ai   Grimmond, Sean M ^ag   Siebert, Reiner ^af   Campo, Elías ^ap   Shibata, Tatsuhiro ^v   Pfister, Stefan M ^t,z   Campbell, Peter J ^a,k,l   Stratton, Michael R ^a,j,aq   more..

^a WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f UNIVERSITY OF GLASGOW   (United Kingdom)

^g GLASGOW ROYAL INFIRMARY   (United Kingdom)

^h GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

ⁱ GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^j Bankstown Hospital ^*  (Germany)

^k BANKSTOWN LIDCOMBE HOSPITAL   (Australia)

^l UNIVERSITY OF NEW SOUTH WALES   (Australia)

^m LUND UNIVERSITY   (Sweden)

ⁿ OSLO UNIVERSITY HOSPITAL   (Norway)

^o UNIVERSITY OF OSLO   (Norway)

^p CENTRE LÉON BÉRARD   (France)

^q UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^r UNIVERSITY HOSPITAL GIESSEN   (Germany)

^s UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^t GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^u UNIVERSITY OF ICELAND   (Iceland)

^v ERASMUS MC CANCER INSTITUTE   (Netherlands)

^w INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^x NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^y INSERM   (France)

^z UNIVERSITÉ PARIS DESCARTES   (France)

^aa BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^ab UNIVERSITY OF BERGEN   (Norway)

^ac HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^ad UNIVERSITY OF QUEENSLAND   (Australia)

^ae UNIVERSITY OF OVIEDO   (Spain)

^af HARVARD MEDICAL SCHOOL   (United States)

^ag VA BOSTON HEALTHCARE SYSTEM   (United States)

^ah NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^ai UNIVERSITY OF QUEENSLAND   (Australia)

^aj DANA FARBER CANCER INSTITUTE   (United States)

^ak BRIGHAM AND WOMEN S HOSPITAL   (United States)

^al UNIVERSITY OF KIEL   (Germany)

^am NETHERLANDS CANCER INSTITUTE   (Netherlands)

^an RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^ao KING'S COLLEGE LONDON   (United Kingdom)

^ap INSTITUT CURIE   (France)

^aq UNIVERSITY OF BARCELONA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYTIDINE DEAMINASE;

AGE; BIOLOGICAL PROCESSES; CANCER; DNA; ETIOLOGY; GENOME; MUTATION;

ARTICLE; B CELL LYMPHOMA; BIOLOGICAL PHENOMENA AND FUNCTIONS CONCERNING THE ENTIRE ORGANISM; BREAST CANCER; CANCER CELL; CANCER DIAGNOSIS; CANCER GENETICS; CHILDHOOD CANCER; CHRONIC LYMPHATIC LEUKEMIA; DNA REPLICATION; DNA STRAND; EXON; GENETIC CODE; HUMAN; HUMAN GENOME; IMMUNOGLOBULIN GENE; INDEL MUTATION; INNATE IMMUNITY; MELANOMA; MISMATCH REPAIR; NEOPLASM; NUCLEIC ACID BASE SUBSTITUTION; PANCREAS CANCER; PRIMARY TUMOR; PRIORITY JOURNAL; SMOKING; SOMATIC CELL; SOMATIC MUTATION; STOMACH CANCER;

EID: 84882837534     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature12666     Document Type: Erratum

References (64)

1. Stratton, M. R., Campbell, P. J. & Futreal, P. A. The cancer genome. Nature 458, 719-724 (2009).
2. Pfeifer, G. P. Environmental exposures and mutational patterns of cancer genomes. Genome Med. 2, 54 (2010).
3. Peñ a-Diaz, J. et al. Noncanonical mismatch repair as a source of genomic instability in human cells. Mol. Cell 47, 669-680 (2012).
4. Olivier, M., Hollstein, M. & Hainaut, P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb. Perspect. Biol. 2, a001008 (2010).
5. Alexandrov, L. B., Nik-Zainal, S., Wedge, D. C., Campbell, P. J. & Stratton, M. R. Deciphering signatures of mutational processes operative in human cancer. Cell Rep. 3, 246-259 (2013).
6. Nik-Zainal, S. et al. Mutational processes molding the genomes of 21 breast cancers. Cell 149, 979-993 (2012).
7. Nik-Zainal, S. et al. The life history of 21 breast cancers. Cell 149, 994-1007 (2012).
8. Hudson, T. J. et al. International network of cancer genome projects. Nature 464, 993-998 (2010).
9. Pfeifer, G. P. Mutagenesis at methylated CpG sequences. Curr. Top. Microbiol. Immunol. 301, 259-281 (2006).
10. Welch, J. S. et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 150, 264-278 (2012).
11. Di Noia, J. M. & Neuberger, M. S. Molecular mechanisms of antibody somatic hypermutation. Annu. Rev. Biochem. 76, 1-22 (2007).
12. Hanawalt, P. C. & Spivak, G. Transcription-coupled DNA repair: two decades of progress and surprises. Nature Rev. Mol. Cell Biol. 9, 958-970 (2008).
13. Pfeifer, G. P. et al. Tobaccosmoke carcinogens,DNA damage andp53mutations in smoking-associated cancers. Oncogene 21, 7435-7451 (2002).
14. Pfeifer, G. P., You, Y. H. & Besaratinia, A. Mutations induced by ultraviolet light. Mutat. Res. 571, 19-31 (2005).
15. Boland, C. R. & Goel, A. Microsatellite instability in colorectal cancer. Gastroenterology 138, 2073-2087 (2010).
16. Thompson, L. H. Recognition, signaling, and repair of DNA double-strand breaks produced by ionizing radiation inmammalian cells: the molecular choreography. Mutat. Res. 751, 158-246 (2012).
17. Hunter, C. et al. A hypermutation phenotype and somatic MSH6 mutations in recurrenthuman malignant gliomas after alkylator chemotherapy. Cancer Res.66, 3987-3991 (2006).
18. Tomita-Mitchell, A. et al. Mismatch repair deficient human cells: spontaneous and MNNG-induced mutational spectra in the HPRT gene. Mutat. Res. 450, 125-138 (2000).
19. Taylor, B. J. M. et al. DNA deaminases induce break-associated mutation showers with implication of APOBEC3B and 3A in breast cancer kataegis. eLife e00534 (2013).
20. Burns, M. B. et al. APOBEC3B is an enzymatic source ofmutation in breast cancer. Nature 494, 366-370 (2013).
21. Harris, R. S., Petersen-Mahrt, S. K. & Neuberger, M. S. RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators. Mol. Cell 10, 1247-1253 (2002).
22. Koito, A. & Ikeda, T. Intrinsic immunity against retrotransposons by APOBEC cytidine deaminases. Front. Microbiol. 4, 28 (2013).
23. Puente, X. S. et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 475, 101-105 (2011).
24. The Cancer Genome AtlasNetwork. Comprehensivemolecularcharacterizationof human colon and rectal cancer. Nature 487, 330-337 (2012).
25. Cancer Genome Atlas Research. Integrated genomic characterization of endometrial carcinoma. Nature 497, 67-73 (2013).
26. Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214-218 (2013).
27. Holmfeldt, L. et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nature Genet. 45, 242-252 (2013).
28. Zhang, J. et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 481, 157-163 (2012).
29. De Keersmaecker, K. et al. Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia. Nature Genet. 45, 186-190 (2013).
30. Ding, L. et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481, 506-510 (2012).
31. Stephens, P. J. et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 486, 400-404 (2012).
32. Quesada, V. et al. Exome sequencing identifies recurrentmutations of the splicing factorSF3B1geneinchronic lymphocytic leukemia. NatureGenet. 44,47-52(2012).
33. Seshagiri, S. et al. Recurrent R-spondin fusions in colon cancer. Nature 488, 660-664 (2012).
34. Dulak, A. M. et al. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nature Genet. 45, 478-486 (2013).
35. Agrawal, N. et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 333, 1154-1157 (2011).
36. Stransky, N. et al. The mutational landscape of head and neck squamous cell carcinoma. Science 333, 1157-1160 (2011).
37. Guo, G. et al. Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma. Nature Genet. 44, 17-19 (2012).
38. Peñ a-Llopis, S. et al. BAP1 loss defines a new class of renal cell carcinoma. Nature Genet. 44, 751-759 (2012).
39. Ding, L. et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455, 1069-1075 (2008).
40. Seo, J. S. et al. The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res. 22, 2109-2119 (2012).
41. Imielinski, M. et al. Mapping the hallmarks of lung adenocarcinomawith massively parallel sequencing. Cell 150, 1107-1120 (2012).
42. Love, C. et al. The genetic landscape of mutations in Burkitt lymphoma. Nature Genet. 44, 1321-1325 (2012).
43. Zhang, J. et al.Whole-genomesequencingidentifies genetic alterations inpediatric low-grade gliomas. Nature Genet. 45, 602-612 (2013).
44. Morin, R. D. et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476, 298-303 (2011).
45. Jiao, Y. et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331, 1199-1203 (2011).
46. Pugh, T. J. et al. The genetic landscape of high-risk neuroblastoma. Nature Genet. 45, 279-284 (2013).
47. Jones, S. et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 330, 228-231 (2010).
48. Wu, J. et al. Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc. Natl Acad. Sci. USA 108, 21188-21193 (2011).
49. Sausen, M. et al. Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nature Genet. 45, 12-17 (2013).
50. Berger, M. F. et al. The genomic complexity of primary human prostate cancer. Nature 470, 214-220 (2011).
51. Grasso, C. S. et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 487, 239-243 (2012).
52. Barbieri, C. E. et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nature Genet. 44, 685-689 (2012).
53. Rudin, C. M. et al.Comprehensive genomic analysis identifiesSOX2 as a frequently amplified gene in small-cell lung cancer. Nature Genet. 44, 1111-1116 (2012).
54. Peifer, M. et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nature Genet. 44, 1104-1110 (2012).
55. Stark, M. S. et al. Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing. Nature Genet. 44, 165-169 (2012).
56. Berger, M. F. et al. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 485, 502-506 (2012).
57. Hodis, E. et al. A landscape of driver mutations in melanoma. Cell 150, 251-263 (2012).
58. Zang, Z. J. et al. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nature Genet. 44, 570-574 (2012).
59. Wang, K. et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nature Genet. 43, 1219-1223 (2011).
60. Sherry, S. T. et al.dbSNP: theNCBI database of genetic variation.Nucleic Acids Res. 29, 308-311 (2001).
61. Abecasis, G. R. et al. An integrated map of genetic variation from 1,092 human genomes. Nature 491, 56-65 (2012).
62. Fu, W. et al. Analysis of 6,515 exomes reveals the recent origin of most human protein-coding variants. Nature 493, 216-220 (2013).
63. Baumbusch, L. O. et al.Comparison of the Agilent,ROMA/NimbleGen and Illumina platforms for classification of copy number alterations in human breast tumors. BMC Genomics 9, 379 (2008).
64. Pickrell, J. K., Gaffney, D. J., Gilad, Y. & Pritchard, J. K. False positive peaks in ChIPseq and other sequencing-based functional assays caused by unannotated high copy number regions. Bioinformatics 27, 2144-2146 (2011).